Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

Jack E Burkhalter, Thomas M Atkinson, J Berry-Lawhorn, Stephen Goldstone, Mark H Einstein, Timothy J Wilkin, Jeannette Lee, David Cella, Joel M Palefsky, ANCHOR HRQOL Implementation Group, Erica I Lubetkin, Jeff Taylor, Nicholas Sheon, Andrew Webb, Susan M Holland, Madeline Rogers, Elyse Shuk, Rebecca Levine, Jack E Burkhalter, Thomas M Atkinson, J Berry-Lawhorn, Stephen Goldstone, Mark H Einstein, Timothy J Wilkin, Jeannette Lee, David Cella, Joel M Palefsky, ANCHOR HRQOL Implementation Group, Erica I Lubetkin, Jeff Taylor, Nicholas Sheon, Andrew Webb, Susan M Holland, Madeline Rogers, Elyse Shuk, Rebecca Levine

Abstract

Background: Anal cancer, caused by oncogenic types of human papillomavirus, is a growing problem in the United States. A key focus of anal cancer prevention has been screening for and treating precancerous high-grade squamous intraepithelial anal lesions (HSILs).

Objectives: To develop a health-related symptom index for HSIL using qualitative techniques because anal HSIL and its treatment may have a negative impact on health-related quality of life (HRQOL), and no HRQOL measure specific to this condition and treatment currently exists.

Methods: Expert consultation was used to guide one-on-one concept elicitation interviews with participants to identify HRQOL aspects they attribute to their anal HSIL and its treatment. This resulted in a draft instrument, which was administered to an independent participant sample, where cognitive interview techniques assessed comprehension.

Results: Eighteen anal HSIL-related concepts were identified by the expert panel. Across the 41 concept elicitation interviews, 23 items representing physical symptoms, physical impacts, and psychological symptoms were identified to comprise the initial measure, which was then evaluated during three rounds of cognitive interviews (n = 45). Several questionnaire aspects were refined on the basis of participant input, with three additional items added per expert/participant recommendation. One item was removed because of poor comprehension, resulting in a 25-item measure.

Conclusions: Using state-of-the-art qualitative methodology, we have established the content validity of this new instrument, the ANCHOR Anal HSIL Health-Related Symptom Index. Quantitative validation efforts are currently underway. The participant-driven process of developing this tool will facilitate a participant-centered evaluation of the impact on morbidity for treatment of anal HSIL or observation without treatment.

Trial registration: ClinicalTrials.gov NCT02836522.

Keywords: ANCHOR trial; health-related quality of life; neoplasms; patient-reported outcomes.

Copyright © 2018 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

References

    1. Nelson RA, Levine AM, Bernstein L, et al. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31(12):1569–1575.
    1. Shiels MS, Kreimer AR, Coghill AE, et al. Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1548–1556.
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute; Bethesda, MD: based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Available from: [Accessed on June 5, 2017]
    1. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med. 2015;163(7):507–518.
    1. Palefsky JM. Anogenital Squamous Cell Cancer and Its Precursors. In: Goedert JJ, editor. Infectious Causes of Cancer: Targets for Intervention. Totowa, NJ: Humana Press; 2000.
    1. Hoots BE, Palefsky JM, Pimenta JM, et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. International journal of cancer. 2009;124(10):2375–2383.
    1. Elam-Evans LD, Yankey D, Jeyarajah J, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2013. Mmwr-Morbid Mortal W. 2014;63(29):625–633.
    1. Palefsky JM. Screening to prevent anal cancer: Current thinking and future directions. Cancer Cytopathol. 2015;123(9):509–510.
    1. Goldstone RN, Hasan SR, Drury S, et al. A trial of radiofrequency ablation for anal intraepithelial neoplasia. Int J Colorectal Dis. 2017;32(3):357–365.
    1. Scholefield JH, Ogunbiyi OA, Smith JH, et al. Treatment of anal intraepithelial neoplasia. Br J Surg. 1994;81(8):1238–1240.
    1. Lyons M, Francis N, Allen-Mersh TG. Treatment of grade 3 anal intraepithelial neoplasia by complete anal mucosal excision without fecal diversion - Report of a case. Diseases of the Colon & Rectum. 1999;42(10):1342–1344.
    1. Pehoushek J, Smith KJ. Imiquimod and 5% Fluorouracil Therapy for Anal and Perianal SquamousCell Carcinoma In Situ in an HIV-1–Positive Man. Archives of dermatology. 2001;137(1):14–16.
    1. Hamdan KA, Tait IS, Nadeau V, et al. Treatment of grade III anal intraepithelial neoplasia with photodynamic therapy: report of a case. Diseases of the colon and rectum. 2003;46(11):1555–1559.
    1. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005;32(Suppl 1):S82–90.
    1. Chang GJ, Berry JM, Jay N, et al. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Diseases of the colon and rectum. 2002;45(4):453–458.
    1. Tinmouth J, Raboud J, Ali M, et al. The psychological impact of being screened for anal cancer in HIV-infected men who have sex with men. Diseases of the colon and rectum. 2011;54(3):352–359.
    1. Siegenbeek van Heukelom ML, Richel O, Nieuwkerk PT, et al. Health-Related Quality of Life and Sexual Functioning of HIV-Positive Men Who Have Sex With Men Who Are Treated for Anal Intraepithelial Neoplasia. Diseases of the colon and rectum. 2016;59(1):42–47.
    1. Bowen GA. Naturalistic inquiry and the saturation concept: a research note. Qual Res. 2008;8(1):137–152.
    1. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough? Field Methods. 2016;18(1):59–82.
    1. Sheon N. Interviews with persons diagnosed and treated for anal HSIL in protocol AMC-076. 2014 Unpublished Manuscript.
    1. Willis GB. Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks, CA: SAGE Publications, Inc; 2005.
    1. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579.
    1. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–988.
    1. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–977.
    1. Centers for Disease Control and Prevention. HIV Surveillance Report. 2015
    1. Gaisa M, Ita-Nagy F, Sigel K, et al. High rates of anal high-grade squamous intraepithelial lesions in HIV-infected women who do not meet screening guidelines. Clinical Infectious Diseases. 2017;64(3):289–294.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する